ArticleEULAR rheumatology open2026
Comparative enthesitis burden in psoriatic arthritis vs axial spondyloarthritis: a cross-sectional analysis of the Swiss Clinical Quality Management in Rheumatic Diseases (SCQM) registry.
Article in EULAR rheumatology open, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objectives: This study aimed to compare prevalence, anatomical distribution, and associated factors of enthesitis in psoriatic arthritis (PsA) and axial spondyloarthritis (axSpA) in routine care. Methods: Cross-sectional analysis of the Swiss Clinical Quality Management in Rheumatic Diseases (SCQM) registry. Patients with PsA or axSpA enrolled from 2018 to 2024 with an available Maastricht Ankylosing Spondylitis Enthesitis Score (MASES) recorded at first visit during study period were included. Enthesitis was defined as a MASES score of > 0. Axial PsA (axPsA) was analysed descriptively for anatomical distribution. Multivariable negative binomial regression modelled entheseal burden, adjusting for age, sex, body mass index (BMI), C-reactive protein levels, symptom duration, and current biologic or targeted synthetic disease-modifying antirheumatic drug use. Results: We included 3885 patients (PsA, 1473; and axSpA, 2412). Enthesitis prevalence was 56.6% in PsA and 64.9% in axSpA. Among patients with any enthesitis, mean MASES score was 2.8 in PsA, 3.0 in axPsA, and 3.2 in axSpA. Posterior superior iliac spine and L5 spinous process were the most frequently affected sites. Achilles tendon involvement was more prominent in PsA and axPsA, whereas costochondral sites were more frequent in axSpA. Female sex, elevated C-reactive protein levels, higher BMI levels, and current smoking were consistently associated with higher enthesitis burden. Longer symptom duration and biologic disease-modifying antirheumatic drug use were associated with lower burden. No differential effects of BMI or smoking by diagnosis or sex were detected. Conclusions: Enthesitis is common in PsA and axSpA, with distinct anatomical patterns but largely shared associated factors. Obesity, smoking, and systemic inflammation may represent relevant targets for intervention alongside pharmacologic management, though longitudinal studies are needed to confirm these associations.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.